eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hypertriglyceridemia |
| Comorbidity | C0948265|metabolic syndrome |
| Sentences | 37 |
| PubMedID- 22219232 | The aim-high trial (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) found, in an interim analysis, no cardiovascular benefit from taking extended-release niacin (niaspan). |
| PubMedID- 21392609 | The atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes (aim-high) trial. |
| PubMedID- 23916935 | Objectives: this study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (cv) outcomes in this secondary analysis of the aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides and impact on global health outcomes) trial. |
| PubMedID- 23990358 | Prandial hypertriglyceridemia in metabolic syndrome is due to an overproduction of both chylomicron and vldl triacylglycerol. |
| PubMedID- 24843436 | The atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides and impact on global health outcomes (aim‐high) study has randomized 3300 patients to receive simvastatin or simvastatin and extended release nicotinic acid. |
| PubMedID- 22520248 | The aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) trial: to believe or not to believe. |
| PubMedID- 24460800 | Acc/aha: american college of cardiology/american heart association; acs: acute coronary syndrome; apo: apolipoprotein; cetp: cholesteryl ester transfer protein; chd: coronary heart disease; ci: confidence interval; cv: cardiovascular; cvd: cardiovascular disease; eas: european atherosclerosis society; epa: eicosapentaenoic acid; er: extended-release; hdl: high-density lipoprotein; ias: international atherosclerosis society; ldl: low-density lipoprotein; mi: myocardial infarction; pcsk9: proprotein convertase subtilisin/kexin type 9; ppar: peroxisome proliferator-activated receptor; r3i: residual risk reduction initiative; spparm: selective peroxisome proliferator-activated receptor modulator; trl: triglyceride-rich lipoprotein; vldl: very low-density lipoprotein; accelerate: a study of evacetrapib in high-risk vascular disease; accord: action to control cardiovascular risk in diabetes; aim-high: atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes; alecardio: aleglitazar in patients with a recent acute coronary syndrome and type 2 diabetes mellitus; assure: apoa-i synthesis stimulation and intravascular ultrasound for coronary atheroma regression evaluation; dysis: dyslipidemia international study; enhance: ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression; field: fenofibrate intervention and event lowering in diabetes; hps2-thrive: heart protection study 2-treatment of hdl to reduce the incidence of vascular events; illuminate: investigation of lipid level management to understand its impact in atherosclerotic events; improve-it: improved reduction of outcomes: vytorin efficacy international trial; jelis: japan eicosapentaenoic acid lipid intervention study; origin: outcome reduction with an initial glargine intervention; posch: program on the surgical control of the hyperlipidemia; procam: prospective cardiovascular münster study; reveal: randomized evaluation of the effects of anacetrapib through lipid-modification; 4s: scandinavian simvastatin survival study; seas: simvastatin and ezetimibe in aortic stenosis; sharp: study of heart and renal protection. |
| PubMedID- 24174878 | After the equivocal aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) study and withdrawal of two major cholesteryl ester transfer protein compounds, one for off-target adverse effects and the other for lack of efficacy, development continues for two other agents, ie, anacetrapib and evacetrapib, both of which lower ldl cholesterol substantially. |
| PubMedID- 22210379 | Mitoq administered orally for 14weeks prevented the increased adiposity, hypercholesterolemia, and hypertriglyceridemia associated with the metabolic syndrome. |
| PubMedID- 21630032 | Moreover, because hypertriglyceridemia is often associated with obesity, diabetes, metabolic syndrome, increased cholesterol levels, disturbed hemostasis and inflammation, some researchers assume that elevated triglyceride levels may be only a non-causal biomarker of future cardiovascular risk [7]. |
| PubMedID- 20715933 | Conclusions: this study suggests that apob and nhdl-c seem to be more correlated to scs in metabolic syndrome with hypertriglyceridemia than ldl-c. |
| PubMedID- 22504910 | Similarly, niacin conferred a significant increase in hdl but failed to reducecardiovascular event rate, leading to early termination of the atherothrombosisintervention in metabolic syndrome with low hdl/high triglycerides: impact on global healthoutcomes (aim-high) trial (6). |
| PubMedID- 21832894 | Aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides and impact on global health outcomes), a trial of statin/niacin, has been prematurely halted for futility. |
| PubMedID- 24363242 | Recently, 2 clinical outcome trials (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides and impact on global health outcomes [aim-high] and second heart protection study [hps-2 thrive]) failed to show a reduction in cv events in patients treated to optimally low levels of ldl-c. |
| PubMedID- 24278833 | Figure 3 showed elevated saturated and monounsaturated fatty acids, which represent a pattern seen in metabolic syndrome with hypertriglyceridemia, where insulin stimulates the liver enzyme fatty acid synthase to produce saturated fatty acids. |
| PubMedID- 23941464 | This chinese cohort study found that liver steatosis was a common condition of hiv patients with hypertriglyceridemia and was associated with male gender, metabolic syndrome, higher triglyceride levels, and higher fasting plasma glucose count as well as certain antiretroviral medications. |
| PubMedID- 22888414 | The aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) trial [31] randomized 3414 with atherosclerotic cardiovascular disease and low levels of hdl-cholesterol to extended-release niacin, 1500 to 2000 mg a day, or placebo. |
| PubMedID- 22723175 | Opinion statement: the premature stopping of the aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health) study due to futility has called into question the clinical value of high-density lipoprotein cholesterol (hdl-c) increases. |
| PubMedID- 22520249 | Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) trial with previous surrogate endpoint trials. |
| PubMedID- 21171671 | However, the ongoing aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides and impact on global health outcomes) is designed to determine the impact of the addition of niacin er to simvastatin as secondary prevention of long-term clinical events in patients with vascular disease and atherogenic dyslipidemia, the majority of whom will have metabolic syndrome. |
| PubMedID- 21376354 | Nonhuman primates (nhps) share with humans many features of lipid metabolism and often develop all features of the metabolic syndrome, including hypertriglyceridemia and low high-density lipoprotein cholesterol, and have been used in many studies of potential therapeutics during the preclinical phase. |
| PubMedID- 24595629 | While this possibility is speculative, the results of the aim high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) trial provide additional evidence of some pertinence (18). |
| PubMedID- 24204156 | Abbreviations: 4s, scandinavian simvastatin survival study; accord, action to control cardiovascular risk in diabetes; afcaps/texcaps, air force/texas coronary atherosceloris prevention study; afregs, armed forces regression study; aim-high, atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes; allhat-llt, antihypertensive and lipid-lowering treatment to prevent heart attack trial; alliance, aggressive lipid-lowering initiation abates new cardiac events; ascot-lla, anglo-scandinavian cardiac outcomes trial--lipid lowering arm; a-z, a to z trial; becait, bezafibrate coronary atherosclerosis intervention trial; bip, bezafibrate infarction prevention; cards, collaborative atorvastatin diabetes study; care, cholesterol and recurrent events; chd, coronary heart disease; cv, cardiovascular; enhance, ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression; field, fenofibrate intervention and event lowering in diabetes; gissi-p. gruppo italiano per lo studio della sopravvivenza nell’infarto miocardico-prevenzione; greace, greek atorvastatin and coronary heart disease evaluation; hats, hdl atherosclerosis treatment study; hers, heart and estrogen/progestin replacement study; hhs, helsinki heart study; hollicos-pat, hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial; hps, heart protection study; ideal, incremental decrease in end points through aggressive lipid lowering; jupiter, justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin; lipid, long-term intervention with pravastatin in ischaemic disease; lrc-cppt, lipid research clinics coronary primary prevention trial; mega, the management of elevated cholesterol in the primary prevention group of adult japanese; meteor, measuring effects on intima-media thickness: an evaluation of rosuvastatin; mi, myocardial infarction; miracl, myocardial ischemia reduction with aggressive cholesterol lowering; nr, not reported; origin, outcome reduction with an initial glargine iintervention; pcabgt, post coronary artery bypass graft trial; plac-i, pravastatin limitation of atherosclerosis in the coronary arteries; prosper, prospective study of pravastatin in the elderly at risk; regress, regression growth evaluation statin study; sparcl, stroke prevention by aggressive reduction in cholesterol levels; stars, st thomas’ atherosclerosis regression study; tc, total cholesterol; tnt, treating to new targets; va-hit, veterans affairs high-density lipoprotein cholesterol intervention trial; woscops, west of scotland coronary prevention study. |
| PubMedID- 21392600 | The atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes (aim-high). |
| PubMedID- 23692373 | Conclusion: children who have received total body irradiation are at risk of diabetes and an exaggerated form of the metabolic syndrome with hypertriglyceridaemia, which can be life-threatening. |
| PubMedID- 22461566 | (2) showed that hypertriglyceridemia in patients with the metabolic syndrome strongly correlates with changes in activity of the autonomic nervous system (ans). |
| PubMedID- 24184942 | Recent findings: recently, the large 'atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes', 'treatment of hdl to reduce the incidence of vascular events' and dal-outcomes studies have challenged the idea that raising hdl cholesterol (hdl-c) decreases cardiovascular disease risk. |
| PubMedID- 20922563 | Background: hypertriglyceridemia subjects with metabolic syndrome exhibit variable postprandial triglyceride responses. |
| PubMedID- 24278817 | The aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health) study, an investigation of 3500 patients with established vascular disease who were treated with up to 2000 mg per day of extended release niacin, failed to find a benefit despite favorable changes in hdl and triglycerides.66 it is interesting to note that these patients were already being treated with statins to an ldl goal below 70 mg/dl. |
| PubMedID- 23881958 | Background and purpose: in atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes (aim-high) trial, addition of extended-release niacin (ern) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental benefit, despite increases in high-density lipoprotein cholesterol. |
| PubMedID- 23736814 | Data from the heart protection 2 treatment of hdl to reduce the incidence of vascular events and the atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health trials both demonstrated no clinical benefit from use of niacin therapy when added to background statin therapy with regard to short-term and long-term cardiovascular risk reduction. |
| PubMedID- 26210594 | Recent large randomized clinical studies - aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides) and hps2-thrive (heart protection study 2-treatment of hdl to reduce the incidence of vascular events) - delivered some disappointing results, leading to the conclusion that no further benefit (decreased parameters of cardiovascular risk) is achieved by adding niacin to existing statin therapy in patients with high cardiovascular risk. |
| PubMedID- 22234788 | We concluded that running exercise restored decreased muscle oxidative capacity and pgc-1alpha mrna levels and improved hypertriglyceridemia in rats with metabolic syndrome. |
| PubMedID- 24184940 | Two cardiovascular outcome trials - atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health trial and hps2-thrive - were both negative. |
| PubMedID- 23265337 | Objectives: this study sought to assess the efficacy of niacin for reducing cardiovascular disease (cvd) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published aim-high (atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes) trial. |
| PubMedID- 22030814 | This monosaccharide is linked to metabolic syndrome, being associated with hypertriglyceridemia, hypertension, insulin resistance and diabetes mellitus. |
| PubMedID- 22431312 | The recently published atherothrombosis intervention in metabolic syndrome with low hdl/high triglycerides: impact on global health outcomes trial (aim-high) included 3414 patients and addressed the question of whether addition of 1.5–2.0 g of er-niacin per day would reduce the risk of major cardiovascular events in patients with established cardiovascular disease and atherogenic dyslipidemia (boden, 2011). |
Page: 1